- Home
- ULS vs INCY Comparison
ULS vs INCY Comparison
Compare ULS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULS | INCY |
|---|---|---|
| Founded | 1894 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 17.0B |
| IPO Year | 2023 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ULS | INCY |
|---|---|---|
| Price | $75.16 | $128.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $88.85 | ★ $103.52 |
| AVG Volume (30 Days) | 982.3K | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 1.66 | 1.47 |
| Revenue | $3,053,000,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $6.29 | $10.44 |
| Revenue Next Year | $5.67 | $10.99 |
| P/E Ratio | ★ $45.34 | $86.54 |
| Revenue Growth | 6.38 | ★ 13.67 |
| 52 Week Low | $62.11 | $81.09 |
| 52 Week High | $107.54 | $132.60 |
Technical Indicators
Market Signals| Indicator | ULS | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 28.80 | 66.03 |
| Support Level | $68.50 | $98.50 |
| Resistance Level | $89.84 | $132.60 |
| Average True Range (ATR) | 2.98 | 3.41 |
| MACD | -0.18 | 0.41 |
| Stochastic Oscillator | 4.38 | 88.27 |
Price Performance
Historical ComparisonAbout ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.